Roche to Acquire GenMark Diagnostics for $1.8B

 Roche to Acquire GenMark Diagnostics for $1.8B

Roche Receives the US FDA’s EUA for cobas SARS-CoV-2 Test to Suspect COVID-19


  • Roche to acquire all outstanding shares of GenMark’s for $24.05/ share in cash, making a total deal value of $1.8B with a premium of ~43% to GenMark’s closing price on Feb 10, 2021. The acquisition is expected to be completed in Q2’21
  • The acquisition will boost Roche’s molecular diagnostics portfolio and will expand the global reach of GenMark’s products
  • GenMark deliver molecular diagnostic tests designed to detect multiple pathogens from a single patient sample and its respiratory pathogen panels complement Roche’s COVID-19 diagnostics solutions

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Switzerland Global Enterprise

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post